UTv Videos

"In terms of results, complete response rate at any time point for the cohort was 74.5%," says Mark D. Tyson, II, MD, MPH.

“The trial is meant to define or test this agent in this population for which currently there's not an established standard of care,” says Robert Svatek, MD.

"That gave us the idea that the diagnostic benefit of extended lymph node detection was pretty minimal," says Leilei Xia, MD.

“There was a wonderful breadth of discussion of some of the key questions that exist within management of bladder cancer right now,” says Sarah P. Psutka, MD, MSc.

"This study basically [looks at] WATER and WATER II over 5 years' follow-up," says Mohamad Baker Berjaoui, MD.

Sieber shares his thoughts on the potential for universal genetic testing to become a standard of care practice for patients with prostate cancer.

"We wanted to explore the outcomes, the compliance rates, [and] the complications with regards to Xiaflex," says Muhammed A. Moukhtar Hammad, MBBCh.

"DTC companies, especially in the men's health space, have really done a wonderful job of destigmatizing conversations," says Justin Dubin, MD.

"Saying 'no' is one of our biggest challenges in our careers as physicians," according to Phillip M. Pierorazio, MD.

"I think that as patients go through this, it's a reminder that it's very scary," says MIchael Jenson, PA-C.

The PRESERVE trial is evaluating the safety and effectiveness of Irreversible electroporation for prostate tissue ablation.

"Things that were typically used to recruit younger physicians need to change because those aren't their priorities anymore," says Kari Bailey, MD.

"But as you get out of expert centers and academic sites that did it for years under research protocols, the level of the quality of the reads decreases," says Jeremie Calais, MD, PhD.

"Honestly, there really isn't another measure of sexual quality of life for females that addresses the specific concerns of the female partners of patients with prostate cancer," says Stacy Loeb, MD, MSc, PhD (hon).

Ernest A. Morton, MD, MBA, MS, spotlights projects looking at the use of AI scribes to assist in notetaking and an AI algorithm to analyze prostate biopsies.

"I'm hopeful that the decisions are more informed in terms of actual science," says Daniel Kwon, MD.

“I think as urologists, we need to become more comfortable with the female pelvic floor,” says Ava Saidian, MD.

"There's something coming out of Canada. It's a kiwi extract, which is a natural collagenase that comes from kiwi," says Landon Trost, MD.

“Before long, what we do, how we do it, and when we do it might solely be based off of those genetic testing results,” says Tim Richardson, MD.

“Time will tell as we move forward, but it has allowed us to use MDT, with or without ADT and ARPIs, to potentially look at hormone-free treatments,” says Jason M. Hafron, MD, CMO.

"I think that now we have good data that patient-reported outcomes have to be considered in these patient populations," says Andrew C. Peterson, MD, MPH.

"This year, we are starting an international rotation with a focus on global health and humanitarian work," says Akanksha Mehta, MD, MS.

"Every practice is going to be a little bit different on how they would like to approach this," says Michael Jenson, PA-C.

"I joke that on face value, the APPs work for me, but I feel like I'm really working for them, because they basically do everything except for the surgery," says Andrew Y. Sun, MD.

"This has been exciting from a physician-surgeon standpoint," says Helen L. Bernie, DO, MPH.

Specifically, Jayram highlights pembrolizumab, nadofaragene firadenovec-vncg, and N-803 (Anktiva).

"Whenever they discuss germline testing, an important part of that is this pretest counseling process where you talk about the pros and the cons," says Daniel Kwon, MD.